| Revision as of 19:21, 21 August 2018 editRblumel (talk | contribs)13 edits Updated his current career info to indicate he is no longer a practicing MD in California← Previous edit | Revision as of 03:41, 8 November 2018 edit undoThecelluloidvoid (talk | contribs)Extended confirmed users5,402 editsmNo edit summaryTag: Visual editNext edit → | ||
| Line 4: | Line 4: | ||
| }} | }} | ||
| '''Carmen Anthony Puliafito'''<ref name=LAT2017/> is an American ]. From 2007 until March 2016 he was dean of the ] |
'''Carmen Anthony Puliafito'''<ref name=LAT2017/> is an American ]. From 2007 until March 2016, he was dean of the ]'s ]. | ||
| == Career == | == Career == | ||
| Line 10: | Line 10: | ||
| Puliafito, who grew up in ], received a degree in medicine from ] and completed a ] in ] and a ] in ] at ]. He has an ] from the ] of the ].<ref name=usc/> | Puliafito, who grew up in ], received a degree in medicine from ] and completed a ] in ] and a ] in ] at ]. He has an ] from the ] of the ].<ref name=usc/> | ||
| He was appointed dean of the ] in December 2007.<ref>USC Press Release. Dec 5 2007. </ref> Before that, he had been director of the ] of the ], and chair of the department of ophthalmology.<ref name=usc>. University of Southern California. Accessed February 2015.{{self-published source|date=February 2015}}</ref> |
He was appointed dean of the ] in December 2007.<ref>USC Press Release. Dec 5 2007. </ref> Before that, he had been director of the ] of the ], and chair of the department of ophthalmology.<ref name=usc>. University of Southern California. Accessed February 2015.{{self-published source|date=February 2015}}</ref> In 2012, he was 21st of the most highly paid research university executives in the United States.<ref>{{cite news | url=http://www.genengnews.com/keywordsandtools/print/3/33096/ | publisher=Genetic Engineering & Biotechnology News | title=25 Top-Paid Research University Leaders | date=Nov 18, 2013 | author=Alex Philippidis|archiveurl=https://web.archive.org/web/20160423085620/http://www.genengnews.com/keywordsandtools/print/3/33096/|archivedate=April 23, 2016}} Accessed February 2015.</ref> | ||
| In March 2016, Puliafito resigned as dean of the Keck School of Medicine, and USC professor ] was appointed interim dean.<ref name="trojan">{{Cite web|url=http://dailytrojan.com/2016/03/24/dean-keck-school-medicine-usc-resigns/|title=Dean of Keck School of Medicine of USC resigns |last=Maamoon|first=Noorhan|website=Daily Trojan|access-date=2016-04-03}}</ref> After leaving USC, he took a role as chief of strategic development with a pharmaceutical company called Ophthotech that was ] new drugs for eye diseases; he was laid off along with 80% of the staff in December 2016 when two ] clinical trials produced negative results.<ref name="LAT2017" /><ref>{{cite news|last1=Adams|first1=Ben|title=Ophthotech cuts to hit around 80% of staffers after phase 3 failures|url=http://www.fiercebiotech.com/biotech/ophthotech-cuts-to-hit-around-80-staffers-after-phase-3-failures|work=FierceBiotech|date=January 17, 2017|language=en}}</ref> | |||
| He has served on the board of the ].<ref>{{cite web|title=Board of Trustees|url=https://www.chla.org/board-trustees|publisher=Children's Hospital Los Angeles|archiveurl=https://web.archive.org/web/20151002100729/http://www.chla.org/board-trustees|archivedate=October 2, 2015}}</ref> | He has served on the board of the ].<ref>{{cite web|title=Board of Trustees|url=https://www.chla.org/board-trustees|publisher=Children's Hospital Los Angeles|archiveurl=https://web.archive.org/web/20151002100729/http://www.chla.org/board-trustees|archivedate=October 2, 2015}}</ref> | ||
| Line 18: | Line 20: | ||
| ==Research== | ==Research== | ||
| Puliafito was one of the inventors of ] |
Puliafito was one of the inventors of ];<ref name=opto/> for this work, ], Eric Swanson and Puliafito received a Rank Prize for Opto-Electronics in 2002.<ref name=opto> (May 2002). . '']'' '''79''' (5): 279–280. Accessed February 2015.</ref> In 2012, Fujimoto, Swanson, and David Huang, with Puliafito and ], received an António Champalimaud Vision Award from the ].<ref name=champ>. Champalimaud Foundation. Accessed February 2015.</ref> | ||
| Puliafito participated in research into the use of ] for the treatment of retinal disorders.<ref name=michels/><ref name=rosenfeld/><ref name=rich/><ref name=mosh/> | Puliafito participated in research into the use of ] for the treatment of retinal disorders.<ref name=michels/><ref name=rosenfeld/><ref name=rich/><ref name=mosh/> | ||
| ==2017 ''Los Angeles Times'' report== | ==2017 ''Los Angeles Times'' report== | ||
| '']'' reported in July 2017 that while Pulafito served as dean and USC professor, he "kept company with a circle of criminals and drug users who said he used methamphetamine and other drugs with them."<ref name=LAT2017>{{cite news|last1=Pringle|first1=Paul|last2=Ryan|first2=Harriet|last3=Elmahrek|first3=Adam|last4=Hamilton|first4=Matt|last5=Parvini|first5=Sarah|title=An overdose, a young companion, drug-fueled parties: The secret life of USC med school dean|url=http://www.latimes.com/local/california/la-me-usc-doctor-20170717-htmlstory.html|work=Los Angeles Times|date=July 17, 2017}}</ref> The reporters reviewed video and photographs of Puliafito engaging in these activities in hotel rooms, apartments, and the dean's office.<ref name=LAT2017/> According to the newspaper, a 21-year-old prostitute had overdosed while taking drugs with Puliafito in a Pasadena hotel room on March 4, 2016; the article included a recording of a conversation between a 911 operator and Puliafito. The report said that police had found methamphetamine in the room.<ref name=LAT2017/> Three weeks later, on March 24, 2016, Puliafito resigned as dean of the Keck School of Medicine.<ref name=trojan/> | |||
| Immediately following the publication of the ''Los Angeles Times'' report, USC announced that Puliafito had been placed "on leave from his roles at USC, including seeing patients."<ref name="Elmahrek">Adam Elmahrek, Sarah Parvini, Paul Pringle & Matt Hamilton, , ''Los Angeles Times'' (July 17, 2017).</ref> | Immediately following the publication of the ''Los Angeles Times'' report, USC announced that Puliafito had been placed "on leave from his roles at USC, including seeing patients."<ref name="Elmahrek">Adam Elmahrek, Sarah Parvini, Paul Pringle & Matt Hamilton, , ''Los Angeles Times'' (July 17, 2017).</ref> | ||
Revision as of 03:41, 8 November 2018
 |
Carmen Anthony Puliafito is an American ophthalmologist. From 2007 until March 2016, he was dean of the University of Southern California's Keck School of Medicine.
Career
Puliafito, who grew up in Buffalo, New York, received a degree in medicine from Harvard Medical School and completed a residency in ophthalmology and a fellowship in vitreoretinal surgery at Massachusetts Eye and Ear Infirmary. He has an MBA from the Wharton School of the University of Pennsylvania.
He was appointed dean of the Keck School of Medicine of USC in December 2007. Before that, he had been director of the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine, and chair of the department of ophthalmology. In 2012, he was 21st of the most highly paid research university executives in the United States.
In March 2016, Puliafito resigned as dean of the Keck School of Medicine, and USC professor Rohit Varma was appointed interim dean. After leaving USC, he took a role as chief of strategic development with a pharmaceutical company called Ophthotech that was developing new drugs for eye diseases; he was laid off along with 80% of the staff in December 2016 when two Phase III clinical trials produced negative results.
He has served on the board of the Children's Hospital Los Angeles.
His license G 88200 in the State of California was revoked based on discipline orders on August 17, 2018.
Research
Puliafito was one of the inventors of optical coherence tomography; for this work, James Fujimoto, Eric Swanson and Puliafito received a Rank Prize for Opto-Electronics in 2002. In 2012, Fujimoto, Swanson, and David Huang, with Puliafito and Joel Schuman, received an António Champalimaud Vision Award from the Champalimaud Foundation.
Puliafito participated in research into the use of bevacizumab for the treatment of retinal disorders.
2017 Los Angeles Times report
The Los Angeles Times reported in July 2017 that while Pulafito served as dean and USC professor, he "kept company with a circle of criminals and drug users who said he used methamphetamine and other drugs with them." The reporters reviewed video and photographs of Puliafito engaging in these activities in hotel rooms, apartments, and the dean's office. According to the newspaper, a 21-year-old prostitute had overdosed while taking drugs with Puliafito in a Pasadena hotel room on March 4, 2016; the article included a recording of a conversation between a 911 operator and Puliafito. The report said that police had found methamphetamine in the room. Three weeks later, on March 24, 2016, Puliafito resigned as dean of the Keck School of Medicine.
Immediately following the publication of the Los Angeles Times report, USC announced that Puliafito had been placed "on leave from his roles at USC, including seeing patients."
References
- ^ Pringle, Paul; Ryan, Harriet; Elmahrek, Adam; Hamilton, Matt; Parvini, Sarah (July 17, 2017). "An overdose, a young companion, drug-fueled parties: The secret life of USC med school dean". Los Angeles Times.
- ^ Carmen Puliafito named new dean of the Keck School of Medicine. University of Southern California. Accessed February 2015.
- USC Press Release. Dec 5 2007. USC Installs Dr. Carmen Puliafito as New Dean of the Keck School of Medicine
- Alex Philippidis (Nov 18, 2013). "25 Top-Paid Research University Leaders". Genetic Engineering & Biotechnology News. Archived from the original on April 23, 2016. Accessed February 2015.
- ^ Maamoon, Noorhan. "Dean of Keck School of Medicine of USC resigns". Daily Trojan. Retrieved 2016-04-03.
- Adams, Ben (January 17, 2017). "Ophthotech cuts to hit around 80% of staffers after phase 3 failures". FierceBiotech.
- "Board of Trustees". Children's Hospital Los Angeles. Archived from the original on October 2, 2015.
- "California Board Of Medicine".
- ^ (May 2002). New Products. Optometry & Vision Science 79 (5): 279–280. Accessed February 2015.
- 2012: Williams & Fujimoto, Huang, Puliafito, Schuman, Swanson. Champalimaud Foundation. Accessed February 2015.
- Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. (2005). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035–47.
- Rosenfeld PJ, Moshfegi AA, Puliafito CA. (2005). Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surgery, Lasers & Imaging 36: 331–5.
- Rich RM, Rosenfeld PJ, Puliafito CA, et al. (2006). Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26: 495–511.
- Moshfegi AA, Rosenfeld PJ, Puliafito CA, et al. (2006). Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 113: 2002–11.
- Adam Elmahrek, Sarah Parvini, Paul Pringle & Matt Hamilton, Former USC medical school dean no longer seeing patients; Pasadena police discipline officer, Los Angeles Times (July 17, 2017).